Cases & Deals

  • Home
  • Practices
  • Celgene licenses patents to Teva for marketing generic version of Focalin capsules and tablets

Share

Celgene licenses patents to Teva for marketing generic version of Focalin capsules and tablets

January 2010

Client(s) Celgene Corporation

Jones Day represented Celgene in its licensing to Teva Pharmaceuticals of patents related to the manufacture of Celgene's Focalin XR capsules and Focalin IR tablets. The licensing was part of a settlement that concluded Hatch-Waxman patent litigation initiated by Celgene and Novartis Pharmaceuticals in response to Teva's filing of an abbreviated new drug application with the US FDA to market a generic equivalent of such drugs.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.